Recent Updates
Recently added Catalysts

AeroVanc

Phase 1

Healthy | Small molecule | Respiratory |Savara, Inc.|Last Updated: Mar 31, 2014

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
ACTIVE_CONTROLLEDDMCBiomarker
Total Trials1
Total Enrollment25
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT01537666Inhaled Vancomycin Tolerability, Safety and PharmacokineticsPHASE1 COMPLETED 25Nov 1, 2011Mar 1, 2012Mar 31, 20142 Australia
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Safety and Tolerability - Number of Participants With Treatment Emergent Adverse Events (TEAEs = Adverse Events That Started During or After the First Dose of Study Drug)
Healthy volunteers = 2 weeks; CF Patients = 1 week

Each participant was monitored regularly for Adverse Events (AEs) throughout the study. The Investigator or designee enquired about AEs by asking participants non-leading questions such as: "How do you feel?" or "Have you had any (other) medical problems since your last visit/assessment?" Additionally, several safety procedures (physical examinations, vital signs, safety laboratory tests, 12-lead ECGs, and spirometry) were conducted on participants at regular intervals. All AEs reported spontaneously by participants or in response to questioning or observation by the Investigator, including those related to safety procedures, were recorded. For each AE, the Investigator recorded the following assessments: seriousness, severity (Mild, Moderate, or Severe), and relationship to study drug (Not Related, Remote, Possible, Probable, or Highly Probable). AEs were considered drug-related if given a relationship of Possible, Probable, or Highly Probable.

Secondary Endpoints
Plasma Pharmacokinetics - Elimination Half Life (t½)
Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours post-dose
Plasma Pharmacokinetics - Time to Reach the Maximum Plasma Concentration (Tmax)
Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours post-dose
Plasma Pharmacokinetics - Maximum Plasma Concentration (Cmax)
Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours post-dose
Unlock Study Endpoints
Study Design & Arms
AllocationNON_RANDOMIZED
MaskingNONE
ModelPARALLEL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
Aerovanc 16 mg in healthy volunteersEXPERIMENTAL -
AeroVanc 32 mg in healthy volunteersEXPERIMENTAL -
AeroVanc 80 mg in healthy volunteersEXPERIMENTAL -
IV vancomycin in healthy volunteersACTIVE_COMPARATOR -
AeroVanc 32 mg in CF patientsEXPERIMENTAL -
AeroVanc 80 mg in CF patientsEXPERIMENTAL -
Interventions
NameTypeDescription
AeroVancDRUGVancomycin hydrochloride dry powder for inhalation
IV vancomycin hydrochlorideDRUGVancomycin hydrochloride solution for intravenous administration
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — 50 Years
SexALL
Healthy VolunteersYes
Study Sites2

Inclusion Criteria Healthy Volunteers: 1. Healthy male volunteers between 18 and 50 years of age inclusive. 2. Able to communicate with site personnel and to understand and voluntarily sign the Informed Consent Form. 3. Able and willing to comply with the Protocol, including availability for all sc...

Countries:Australia
Unlock Eligibility Criteria